South Shore Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

South Shore Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,500	Closed	-$549K	–	169
2025 Q4	$549K	Buy	+4,500	New	+$516K	0.4%	54

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

South Shore Capital Advisors's XBI Position: Q1 2026 in Review

South Shore Capital Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 4,500 shares — an estimated $549K sold.

South Shore Capital Advisors first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $549K in Q4 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

South Shore Capital Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
South Shore Capital Advisors sold 4,500 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $549K.
South Shore Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
South Shore Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $549K in Q4 2025.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on South Shore Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.